Short answer
Teladoc Health, Inc. (TDOC) filed its Q3 2025 10-Q quarterly report on Oct 30, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $626M (down 2.2% year over year) with net income of −$50M.
Q3 2025 key financials · XBRL
- Revenue
- $626M
- −2.2% YoY · −0.9% QoQ
- Net income
- −$50M
- −48.8% YoY · −51.6% QoQ
- Operating margin
- -8.3%
- EPS (diluted)
- −$0.28
- −64.7% YoY · −47.4% QoQ
Source: XBRL data from the Teladoc Health, Inc. (TDOC) Q3 2025 10-Q on SEC EDGAR. USD.
Teladoc Health, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New operational risk: CFO Mala Murthy resignation effective Nov 21, 2025, CEO Charles Divita to serve as interim principal financial officer
- Financial risk update: Credit Agreement dated July 17, 2025, with JPMorgan Chase Bank as administrative agent executed July 23, 2025
- Regulatory/compliance risk: Adoption of Rule 10b5-1 trading plans by President and Board member for up to 10,000 shares sales and purchases through late 2025
- Market risk: Leadership transition may impact near-term strategic execution and investor confidence
- No new currency or liquidity risks specifically disclosed in this filing
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Teladoc Health, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.